甲状腺微小乳头状癌复发危险因素的网状Meta分析

doi:10.13481/j.1671-587X.20230613

Abstract

Abstract:

Objective To discuss the risk factors of recurrence of papillary thyroid microcarcinoma （PTMC），and to provide the reference for the individualized diagnosis and treatment of PTMC. Methods The retrieval time was limited from the establishment to April 2022， and the case-control studies related to PTMC recurrence searched in PubMed， EMBase， Elsevier Science Direct and Web of Science Databases were collected.Review Manager 5.4 software was used to perform the Meta-analysis and ADDIS 1.16.8 software was used to make the Bayesian network Meta-analysis，and the risk factors of PTMC recurrence were screened out and ranked. Results Fourteen studies were included， involving 7 834 PTMC patients who underwent surgical treatment，302 patients experienced lymphnode recurrence， local thyroid bed recurrence， or distant metastasis recurrence. Age， multifocality， tumor size， extrathyroidal invasion， lymphnode metastasis， and vascular invasion of the patients were related to the PTMC recurrence （P<0.05）. Lymphnode metastasis was the most significant risk factor for the PTMC recurrence， followed by vascular invasion， and multifocality was the least significant risk factor. There were no significant correlations between gender， lesion histopathological background， gland histopathological background， radioactive iodine treatment， surgical margin， and the extent of thyroidectomy with PTMC recurrence （P>0.05）. Conclusion Lymphnode metastasis， vascular invasion， tumor size>5 mm，age，extrathyroidal invasion， and multifocality are the risk factors for the PTMC recurrence.The clinician may consider to treat the PTMC patients with routine central lymphnode dissection to prevent disease recurrence，and develop the individualized treatment plans based on the risk factor stratification.

Key words: Papillary thyroid microcarcinoma, Recurrence, Risk factor, Reticulated Meta-analysis, Lymphnode metastasis

CLC Number:

R736.1

Peng QI,Xianying MENG,Meihua PIAO,Qiang ZHANG. Network Meta-analysis on risk factors of recurrence of papillary thyroid microcarcinoma[J].Journal of Jilin University(Medicine Edition), 2023, 49(6): 1504-1512.

Figures/Tables 8

Fig. 1

Tab. 1

Fig. 2

Tab. 2

Fig. 3

Fig. 4

Tab. 3

Tab. 4

References 40

1	VAN DIJK S P J， COERTS H I， LONCAR I， et al. Deescalating follow-up after hemithyroidectomy for patients with low-risk papillary thyroid microcarcinoma［J］. JAMA Otolaryngol Head Neck Surg， 2023， 149（1）： 42-48.
2	SUGITANI I. Active surveillance of low-risk papillary thyroid microcarcinoma［J］. Best Pract Res Clin Endocrinol Metab， 2023， 37（1）： 101630.
3	WALGAMA E， SACKS W L， HO A S. Papillary thyroid microcarcinoma： optimal management versus overtreatment［J］. Curr Opin Oncol， 2020， 32（1）： 1-6.
4	LIU Z M， WANG L Q， YI P F， et al. Risk factors for central lymph node metastasis of patients with papillary thyroid microcarcinoma： a meta-analysis［J］. Int J Clin Exp Pathol， 2014， 7（3）： 932-937.
5	SASAKI T， MIYAUCHI A， FUJISHIMA M， et al. Comparison of postoperative unfavorable events in patients with low-risk papillary thyroid carcinoma： immediate surgery versus conversion surgery following active surveillance［J］. Thyroid， 2023， 33（2）： 186-191.
6	SUGITANI I， ITO Y， TAKEUCHI D， et al. Indications and strategy for active surveillance of adult low-risk papillary thyroid microcarcinoma： consensus statements from the Japan association of endocrine surgery task force on management for papillary thyroid microcarcinoma［J］. Thyroid， 2021， 31（2）： 183-192.
7	ITO Y， URUNO T， NAKANO K， et al. An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid［J］. Thyroid， 2003， 13（4）： 381-387.
8	SUGITANI I， FUJIMOTO Y. Symptomatic versus asymptomatic papillary thyroid microcarcinoma：a retrospective analysis of surgical outcome and prognostic factors［J］. Endocr J， 1999， 46（1）： 209-216.
9	HAUGEN B R， ALEXANDER E K， BIBLE K C，et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer： the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer［J］. Thyroid， 2016， 26（1）： 1-133.
10	ZHAO H Q， LI H H. Meta-analysis of ultrasound for cervical lymph nodes in papillary thyroid cancer： diagnosis of central and lateral compartment nodal metastases［J］. Eur J Radiol， 2019， 112： 14-21.
11	ZHANG L， WEI W J， JI Q H， et al. Risk factors for neck nodal metastasis in papillary thyroid microcarcinoma： a study of 1066 patients［J］. J Clin Endocrinol Metab， 2012， 97（4）： 1250-1257.
12	SIDDIQUI S， WHITE M G， ANTIC T， et al. Clinical and pathologic predictors of lymph node metastasis and recurrence in papillary thyroid microcarcinoma［J］. Thyroid， 2016， 26（6）： 807-815.
13	LEE J， SONG Y， SOH E Y. Central lymph node metastasis is an important prognostic factor in patients with papillary thyroid microcarcinoma［J］. J Korean Med Sci， 2014， 29（1）： 48-52.
14	SEITIDIS G， NIKOLAKOPOULOS S， HENNESSY E A， et al. Network meta-analysis techniques for synthesizing prevention science evidence［J］. Prev Sci， 2022， 23（3）： 415-424.
15	PAGE M J， MCKENZIE J E， BOSSUYT P M， et al. The PRISMA 2020 statement： an updated guideline for reporting systematic reviews［J］. J Clin Epidemiol， 2021， 134： 178-189.
16	ROSS D S， LITOFSKY D， AIN K B， et al. Recurrence after treatment of micropapillary thyroid cancer［J］. Thyroid， 2009， 19（10）： 1043-1048.
17	GIORDANO D， GRADONI P， ORETTI G， et al. Treatment and prognostic factors of papillary thyroid microcarcinoma［J］.Clin Otolaryngol，2010，35（2）：118-124.
18	LOMBARDI C P， BELLANTONE R， CREA C D，et al.Papillary thyroid microcarcinoma： extrathyroidal extension， lymph node metastases， and risk factors for recurrence in a high prevalence of goiter area［J］. World J Surg， 2010， 34（6）： 1214-1221.
19	MERCANTE G， FRASOLDATI A， PEDRONI C，et al.Prognostic factors affecting neck lymph node recurrence and distant metastasis in papillary microcarcinoma of the thyroid： results of a study in 445 patients［J］. Thyroid， 2009， 19（7）： 707-716.
20	KIM K J， KIM S M， LEE Y S， et al. Prognostic significance of tumor multifocality in papillary thyroid carcinoma and its relationship with primary tumor size： a retrospective study of 2， 309 consecutive patients［J］. Ann Surg Oncol， 2015， 22（1）： 125-131.
21	CALISKAN M， PARK J H， JEONG J S， et al. Role of prophylactic ipsilateral central compartment lymph node dissection in papillary thyroid microcarcinoma［J］. Endocr J， 2012， 59（4）： 305-311.
22	CHOW S M， LAW S C， CHAN J K， et al. Papillary microcarcinoma of the thyroid-Prognostic significance of lymph node metastasis and multifocality［J］. Cancer， 2003， 98（1）： 31-40.
23	CREACH K M， SIEGEL B A， NUSSENBAUM B， et al. Radioactive iodine therapy decreases recurrence in thyroid papillary microcarcinoma［J］. ISRN Endocrinol， 2012， 2012： 816386.
24	BESIC N， PILKO G， PETRIC R， et al. Papillary thyroid microcarcinoma： prognostic factors and treatment［J］. J Surg Oncol， 2008， 97（3）： 221-225.
25	LEE C R， SON H， LEE S， et al. Lobectomy and prophylactic central neck dissection for papillary thyroid microcarcinoma： do involved lymph nodes mandate completion thyroidectomy？［J］.World J Surg，2014，38（4）： 872-877.
26	GAO R， JIA X， LIANG Y Q， et al. Papillary thyroid micro carcinoma： the incidence of high-risk features and its prognostic implications［J］. Front Endocrinol， 2019， 10： 74.
27	CHO J K， KIM J Y， JEONG C Y， et al. Clinical features and prognostic factors in papillary thyroid microcarcinoma depends on age［J］. J Korean Surg Soc， 2012， 82（5）： 281-287.
28	VARGAS-PINTO S， ROMERO ARENAS M A. Lobectomy compared to total thyroidectomy for low-risk papillary thyroid cancer： a systematic review［J］. J Surg Res， 2019， 242： 244-251.
29	ZHAO H Q， CUI L.Extent of surgery and the prognosis of unilateral papillary thyroid microcarcinoma［J］. Front Endocrinol， 2021， 12： 655608.
30	KOOT A， SOARES P， ROBENSHTOK E， et al. Position paper from the Endocrine Task Force of the European Organisation for Research and Treatment of Cancer （EORTC） on the management and shared decision making in patients with low-risk micro papillary thyroid carcinoma［J］. Eur J Cancer， 2023， 179： 98-112.
31	HARTL D M， MAMELLE E， BORGET I， et al. Influence of prophylactic neck dissection on rate of retreatment for papillary thyroid carcinoma［J］. World J Surg， 2013， 37（8）： 1951-1958.
32	GUO K， WANG Z Y. Risk factors influencing the recurrence of papillary thyroid carcinoma： a systematic review and meta-analysis［J］. Int J Clin Exp Pathol， 2014， 7（9）： 5393-5403.
33	YIN X J， LIU C P， GUO Y W， et al. Influence of tumor extent on central lymph node metastasis in solitary papillary thyroid microcarcinomas： a retrospective study of 1092 patients［J］.World J Surg Oncol，2017，15（1）：133.
34	WADA N， DUH Q Y， SUGINO K， et al. Lymph node metastasis from 259 papillary thyroid microcarcinomas： frequency， pattern of occurrence and recurrence， and optimal strategy for neck dissection［J］. Ann Surg， 2003， 237（3）： 399-407.
35	ZHENG X Q， PENG C， GAO M， et al. Risk factors for cervical lymph node metastasis in papillary thyroid microcarcinoma： a study of 1， 587 patients［J］. Cancer Biol Med， 2019， 16（1）： 121-130.
36	ZHAO Q Z， MING J， LIU C P， et al. Multifocality and total tumor diameter predict central neck lymph node metastases in papillary thyroid microcarcinoma［J］. Ann Surg Oncol， 2013， 20（3）： 746-752.
37	CALÒ P G， PISANO G， MEDAS F， et al. Total thyroidectomy without prophylactic central neck dissection in clinically node-negative papillary thyroid cancer： is it an adequate treatment？［J］. World J Surg Oncol， 2014， 12： 152.
38	SHAN C X， ZHANG W， JIANG D Z， et al. Routine central neck dissection in differentiated thyroid carcinoma： a systematic review and meta-analysis［J］. Laryngoscope， 2012， 122（4）： 797-804.
39	XUE S， WANG P S， LIU J， et al. Prophylactic central lymph node dissection in cN₀ patients with papillary thyroid carcinoma： a retrospective study in China［J］. Asian J Surg， 2016， 39（3）： 131-136.
40	SO Y K， SEO M Y， SON Y I. Prophylactic central lymph node dissection for clinically node-negative papillary thyroid microcarcinoma： influence on serum thyroglobulin level， recurrence rate， and postoperative complications［J］. Surgery， 2012， 151（2）： 192-198.

Study	Country	Year	Follow-up duration（year）	Recorded /Total patients (η/%)	Risk factors	NOS score
ROSS et al ^[16]	American	2009	3.0－4.0	38/611 (6.2)	3, 6, 10,13	8
LEE et al ^[13]	Korea	2013	3.0	41/2018 (2.0)	1, 2, 3, 5, 4, 8, 10, 13	9
SUGITANI et al ^[8]	Japan	1999	12.0	13/178 (7.3)	1, 3, 5, 4, 6, 8	7
GIORDANO et al ^[17]	Italy	2010	3.6	9/97 (9.3)	1, 2, 3, 5, 4, 6, 9, 10, 7	8
CELESTINO et al ^[18]	Italy	2010	3.0±1.7	9/287 (3.1)	1, 2, 6, 9, 11	9
MERCANTE et al ^[19]	Italy	2008	5.3	17/389 (4.4)	1, 2, 3, 5, 4, 6, 11	8
KIM et al ^[20]	Korea	2015	5.6	36/1661 (2.2)	1, 2, 3, 5, 4, 6, 13	9
CALISKAN et al ^[21]	Korea	2012	5.4±1.8	19/842 (2.3)	1, 2, 3, 5, 4, 6, 13	9
CHOW et al ^[22]	China	2003	8.5	12/203 (5.9)	1, 2, 3, 5, 4, 6, 10, 11, 13	8
CREACH et al ^[23]	American	2011	5.3	40/407 (9.8)	1, 2， 3, 5, 6, 10, 7, 12	9
BESIC et al ^[24]	Slovenia	2008	7.0	7/228 (3.1)	1, 2, 3, 5, 4, 6, 8, 7, 12	8
LEE et al ^[25]	Korea	2013	12.7	21/281 (7.5)	1, 2, 3, 5, 4	9
GAO et al ^[26]	China	2019	1.5	23/158 (14.6)	1, 3, 5, 4, 9, 7	9
CHO et al ^[27]	Korea	2012	4.0±2.0	17/474 (3.6)	1, 2, 3, 5, 9, 6, 10, 13	7

Risk factor	Rank 1	Rank 2	Rank 3	Rank 4	Rank 5	Rank 6
Extrathyroidal extension	<0.01	0.07	0.19	0.24	0.27	0.23
Multifocality	<0.01	0.03	0.12	0.18	0.28	0.38
Vascular invasion	0.22	0.42	0.10	0.07	0.06	0.13
Age	<0.01	0.11	0.25	0.25	0.22	0.17
Lymphnode metastasis	0.77	0.22	<0.01	<0.01	<0.01	<0.01
Tumor size	<0.01	0.14	0.34	0.26	0.17	0.09

Parameter	OR (95% CI)
Random effects standard deviation (consistency model)	0.57 (0.37—0.83)
Random effects standard deviation (inconsistency model)	0.58 (0.38—0.84)
Inconsistency standard deviation	0.19 (0—0.85)

Risk factor	Direct effect OR (95%CI)	Indirect effect OR (95%CI)	Overall OR (95%CI)	P
Age vs lymphnode metastasis	0.62 (0.10—1.16)	1.06 (0.17—1.97)	0.68 (0.21—1.18)	0.38
Age vs tumor size	0.03 (－0.43—0.49)	0.26 (－0.57—1.06)	0.06 (－0.39—0.51)	0.61
Age vs vascular invasion	0.43 (－0.79—1.55)	－0.22 (－2.11—1.40)	0.33 (－0.64—1.21)	0.52
Extrathyroidal extension vs lymphnode metastasis	0.72 (0.22—1.23)	0.41 (－0.64—1.47)	0.72 (0.24—1.21)	0.58
Extrathyroidal extension vs tumor size	0.06 (－0.39—0.51)	0.85 (－0.73—2.45)	0.10 (－0.36—0.54)	0.32
Lymphnode metastasis vs multifocality	－0.75 (－1.23—－0.30)	－0.90 (－1.80—－0.05)	－0.79 (－1.26—－0.33)	0.75
Lymphnode metastasis vs tumor size	－0.74 (－1.25—－0.26)	－0.38 (－1.15—0.38)	－0.63 (－1.10—－0.17)	0.39
Lymphnode metastasis vs vascular invasion	－0.12 (－1.41—1.05)	－0.88 (－2.71—0.73)	－0.36 (－1.35—0.54)	0.45
Multifocality vs tumor size	0.12 (－0.34—0.55)	0.92 (－0.67—2.49)	0.16 (－0.27—0.62)	0.32
Tumor size vs vascular invasion	0.19 (－0.99—1.31)	0.67 (－1.19—2.27)	0.27 (－0.69—1.14)	0.64

[1]	Xue DONG,Jinfeng ZANG,Caifeng XU,Hebing LIU,Zhaohua CHENG. Construction and validation of risk prediction model of enteral nutrition feeding intolerance of patients with severe acute pancreatitis [J]. Journal of Jilin University(Medicine Edition), 2023, 49(6): 1586-1592.
[2]	Xiunan FENG,Lu CHEN,Yu LONG,Zhenyu JIANG,Ling ZHAO. Analysis on clinical characteristics and risk factors of patients with Sjogren’s syndrome complicated with interstitial lung disease [J]. Journal of Jilin University(Medicine Edition), 2023, 49(6): 1513-1518.
[3]	Tong SHEN,Yang WANG,Wei JIN,Zhihui LIN,Li YAN. Risk factors analysis and risk model construction of cognitive frailty in elderly patients with chronic diseases [J]. Journal of Jilin University(Medicine Edition), 2023, 49(5): 1304-1309.
[4]	Mingfei JU,Chao LIU,Zhigang MA,Juan ZHAO,Tu WANG,Zhihao WANG. Predictive value of residual cholesterol in occurrence of patients with acute coronary syndrome [J]. Journal of Jilin University(Medicine Edition), 2023, 49(3): 765-769.
[5]	Lianyuan WANG,Yi YANG,Huiwen CONG,Haohua WANG,Qihan BAO,Chengsheng LI,Liwen ZHOU,Zichen DING,Yanli LI,Fuyan SHI,Suzhen WANG. Bayesian quantile regression joint model analysis on risk factors of Alzheimer’s disease in people with different MMSE scores [J]. Journal of Jilin University(Medicine Edition), 2023, 49(2): 395-401.
[6]	Rongxia JIA,Xu ZHOU,Zhikun SHI,Meijing BAO,Guanqun WANG,Yuqing CHU,Yang JIN,Yang LIN. Recurrent vulvar angiomyofibroblastoma :A case report and literature review [J]. Journal of Jilin University(Medicine Edition), 2023, 49(1): 193-197.
[7]	Yunhe GAO,Jianan YAO,Lanqing CAO,Chuanjie XU. Clinicopathological characteristics and analysis on prognostic factors of patients with solitary fibrous tumors in different sites [J]. Journal of Jilin University(Medicine Edition), 2022, 48(6): 1510-1517.
[8]	Lina SONG,Chunyue WU,Qingyan QIN,Tianshu CHU,Qilin LIU. Familial multiple odontogenic keratocysts：A report of two cases and literature review [J]. Journal of Jilin University(Medicine Edition), 2022, 48(4): 1035-1039.
[9]	Shan GAO,Yutong WANG,Minqiu LU,Lei SHI,Bin CHU,Yuehua DING,Mengzhen WANG,Li BAO. Analysis on causes for early death and its risk factors of patients with multiple myeloma in era of novel drugs [J]. Journal of Jilin University(Medicine Edition), 2022, 48(3): 783-789.
[10]	Wei WANG,Baisong LIN,Haixing LIAN,Xudong GUO,Chen CHEN,Xiuhe ZHANG. Atypical bilocular myxoma:A case report and literature review [J]. Journal of Jilin University(Medicine Edition), 2022, 48(2): 500-504.
[11]	ZHANG Yiqun, JIANG Weibo, YUAN Sheng, YU Wei. Analysis on follow-up results of postoperative function and recurrence of 23 patients with tenosynovial giant cell tumor in hand [J]. Journal of Jilin University(Medicine Edition), 2020, 46(05): 1061-1064.
[12]	ZHANG Haolong, YU Zhentao, GAO Zihan, WU Yuanyu, FANG Xuedong. Related risk factors and clinical treatment of patients with PGS after gastric cancer operation [J]. Journal of Jilin University(Medicine Edition), 2019, 45(03): 673-677.
[13]	DUAN Jiqing, SUO Jian, SUN Donghui. Application of two-step procedure to turn rectum out from abdominal cavity in radical resection of low rectal carcinoma by natural orifice specimen extraction surgery: A report of 39 cases [J]. Journal of Jilin University(Medicine Edition), 2019, 45(03): 683-687.
[14]	WANG XI, HAN Jinhua, LI Yunfeng, YANG Yanming. Observation on short-term efficacy of thermal-therapy combined with ¹²⁵I particles in treatment of recurrent rectal cancer [J]. Journal of Jilin University Medicine Edition, 2017, 43(05): 963-966.
[15]	JIANG Rui, LIU Fang, PAN Yueji, LU Boyang, HOU Lulu, WANG Chunmei, JIA Hui, SHI Xiaoru. Screening and analysis of dry eye in eye discomfort patients in Jilin Province [J]. Journal of Jilin University Medicine Edition, 2017, 43(04): 832-838.

Network Meta-analysis on risk factors of recurrence of papillary thyroid microcarcinoma

RichHTML

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 8

References 40

Related Articles 15

Metrics

Comments

Recommended 0